Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
17 June 2008 - 10:00PM
PR Newswire (US)
ARLINGTON, Va., June 17 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs, today
announced that it has begun preclinical development of the lead
Benzoylphenylurea (BPU) sulfur analog compound that the Company
acquired last year. The compound has shown promising activity
against in vitro and in vivo models of prostate and pancreatic
cancer. Preclinical supplies of the drug substance have been
recently secured and the preclinical development process is being
initiated. Champions Biotechnology intends to test the BPU Agent
utilizing its Biomerk Tumorgraft(TM) Preclinical Platform. Studies
utilizing Biomerk Tumorgrafts are conducted like Phase II clinical
trials and leading pharmaceutical companies are utilizing the
Platform because it is believed to be more predictive than
traditional preclinical models. "We believe that our Biomerk
Tumorgrafts accurately predict the outcome of Phase II clinical
trials at the early preclinical stage. This provides an enormous
advantage versus traditional preclinical models. By testing the BPU
Agent against panels of Biomerk Tumorgrafts from several different
cancer types, we should be able to identify the compound's best
application, predict the outcome of Phase II human trials and, if
appropriate, discover biomarkers that may accelerate its clinical
development," stated Champions Biotechnology's Chief Scientific
Officer, Manual Hidalgo, M.D., Ph.D. Champions Biotechnology's BPU
Agent is an antimitotic inhibitor that targets MAPT
(Microtubule-Associated Protein Tau) deficient tumors, a common
feature of solid tumors (Molecular Cancer Therapeutics, 2007; 6(5):
1509- 1516). The Company, in exchange for 550,000 restricted shares
of its common stock, was assigned all the rights in the U.S. and in
foreign countries to the applications for these inhibitors
developed at Johns Hopkins University by their inventors Drs. Saeed
Khan, Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno. For
more information regarding Champions Biotechnology's growing
business and recent news, please visit
http://www.championsbiotechnology.com/. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and predictive tumor
specific data to enhance and accelerate the value of oncology
drugs. The Company's Preclinical Platform is a novel approach based
upon the implantation of primary human tumors in immune deficient
mice followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. The Company believes
that these Tumorgrafts closely reflect human cancer biology and
their response to drugs is more predictive of clinical outcomes in
cancer patients. Champions Biotechnology leverages its preclinical
platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates through pre-clinical trials. As drugs
progress through this early stage of development, the Company plans
to sell, partner or license them to pharmaceutical and/or
biotechnology companies, as appropriate. The Company also offers
its predictive preclinical platform and tumor specific data to
physicians for personalized patient care and to companies for
evaluation of oncology drugs and drug candidates in models that
integrate prognostic testing with biomarker discovery. Champions
Biotechnology is dedicated to enhancing preclinical development
tools, accelerating development and valuation of oncology drugs,
and advancing personalized treatment with a goal to improve the
lives of cancer patients globally. This press release contains
"forward-looking statements" (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-KSB for the fiscal year ended
April 30, 2007 for a discussion of such risks, uncertainties and
other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Biotechnology's future results, levels of
activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE:
http://www.championsbiotechnology.com/ DATASOURCE: Champions
Biotechnology, Inc. CONTACT: James Martell of Champions
Biotechnology, +1-410-630-1313
Copyright